BioCentury
ARTICLE | Financial News

Immune Design, Tobira, Zosano file for IPO

June 25, 2014 12:24 AM UTC

Immune Design Corp. (Seattle, Wash.), Tobira Therapeutics Inc. (San Francisco, Calif.) and Zosano Pharma Corp. (Fremont, Calif.) filed to raise money in IPOs on NASDAQ. Immune Design is looking to raise up to $60 million. Jefferies; Leerink Partners; and Wells Fargo are underwriters. In 1Q15, Immune Design expects Phase I data for LV305 to treat solid tumors and for GL-100 to treat Merkel cell carcinoma. LV305 is a lentiviral vector engineered to deliver antigen-encoding nucleic acids directly to dendritic cells in vivo, and GL-100 is a toll-like receptor 4 (TLR4) agonist (see BioCentury, Nov. 4, 2013).

Tobira is aiming to raise up to $69 million. BMO Capital Markets; JMP Securities; Oppenheimer; and Nomura are underwriters. Tobira's cenicriviroc has completed a Phase IIb trial to treat HIV infection, but Tobira plans to advance the compound for the indication with a partner or with non-dilutive financing. Next half, Tobira plans to start a Phase II trial of the dual CC chemokine receptor 5 ( CCR5; CD195) and CCR2 antagonist to treat non-alcoholic steatohepatitis (NASH). Tobira has exclusive, worldwide rights to cenicriviroc from Takeda Pharmaceutical Co. Ltd. (Tokyo:4502). ...